Clinical and Electrophysiological Profiles in Early Recognition of POEMS Syndrome

0
0
0

Clinical and Electrophysiological Profiles in Early Recognition of POEMS Syndrome

POEMS syndrome, an acronym for polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes, is a rare paraneoplastic disorder associated with plasma cell dyscrasia. Early diagnosis remains challenging, as polyneuropathy—often the initial manifestation—mimics chronic inflammatory demyelinating polyneuropathy (CIDP), a more common acquired demyelinating neuropathy. Misdiagnosis delays appropriate treatment, underscoring the need to identify distinguishing clinical and electrophysiological features. This study compares 17 POEMS syndrome patients with 17 CIDP patients to delineate key diagnostic markers, emphasizing the integration of clinical presentation, laboratory findings, and neurophysiological data.

Clinical Presentation and Systemic Features

Patients with POEMS syndrome exhibited distinct multisystem involvement compared to CIDP. Neuropathic pain in the lower extremities was significantly more prevalent in POEMS (58.8% vs. 11.8%, P = 0.01). This pain, described as pricking, burning, or pressure-like, followed a length-dependent pattern, contrasting with CIDP’s insensate neuropathy. Systemic manifestations further differentiated the groups:

  • Edema (82.4% vs. 5.9%, P < 0.001) and ascites (52.9% vs. 0%) were common in POEMS.
  • Organomegaly (82.4% vs. 0%) and skin changes (76.5% vs. 5.9%, P < 0.001), such as hyperpigmentation or hypertrichosis, were exclusive to POEMS.
  • Thrombocytosis (41.2% vs. 0%, P = 0.007) and endocrine abnormalities (52.9% vs. 11.8%, P = 0.026) further supported POEMS diagnosis.

These systemic features, combined with neuropathy, provide early clues for POEMS suspicion, even when serum monoclonal protein (M-protein) is initially undetected.

Electrophysiological Differentiation

Nerve conduction studies revealed distinct patterns between POEMS and CIDP. While both groups exhibited demyelinating features (prolonged distal motor latency [DML], reduced conduction velocity), key differences emerged:

  1. Terminal Latency Index (TLI):

    • TLI, measuring distal vs. intermediate nerve segment conduction, was significantly higher in POEMS (median nerve: 0.39 vs. 0.30, P = 0.016; ulnar nerve: 0.55 vs. 0.42, P = 0.042).
    • Elevated TLI (>0.40 for median nerve, >0.49 for ulnar nerve) indicated predominant intermediate segment demyelination in POEMS, whereas CIDP showed distal predominance.

  2. Axonal Loss and CMAP Patterns:

    • POEMS demonstrated severe axonal loss in lower extremities: absent tibial CMAP (52.9% vs. 17.6%, P = 0.031) and reduced tibial/median CMAP amplitude ratio (0 vs. 0.20, P = 0.049).
    • CIDP had higher rates of conduction block (ulnar nerve: 35.3% vs. 0%, P = 0.018) and temporal dispersion (median nerve: 58.8% vs. 17.6%, P = 0.032), reflecting multifocal demyelination.

  3. Sensory Nerve Abnormalities:

    • POEMS showed slower sensory conduction velocities in upper extremities (median nerve: 40.0 m/s vs. 47.7 m/s, P = 0.006), while both groups had frequent absent sensory potentials in lower limbs.

These findings highlight POEMS’s uniform demyelination with distal axonal degeneration, contrasting with CIDP’s heterogeneous demyelination.

Diagnostic Utility of Serum Markers and TLI

Serum M-protein detection and TLI analysis proved critical for early diagnosis:

  • Serum M-protein (IgA/IgG) had 64.7% sensitivity and 100% specificity but was initially negative in 35.3% of POEMS patients. Repeat testing or tissue biopsies (bone marrow, subcutaneous fat) confirmed clonal plasma cells in these cases.
  • Elevated TLI alone showed 70.6% sensitivity and 76.5% specificity.
  • Combining M-protein and TLI increased sensitivity to 94.1% (if either marker was positive), with specificity maintained at 76.5%. When both markers were present, specificity reached 100%, albeit with lower sensitivity (47.1%).

This strategy optimizes diagnostic accuracy, particularly when initial serum tests are negative.

Pathophysiological and Therapeutic Implications

POEMS neuropathy arises from plasma cell dyscrasia, with vascular endothelial growth factor (VEGF) overexpression contributing to microvascular permeability and nerve damage. Unlike CIDP’s immune-mediated demyelination, POEMS involves uniform demyelination and secondary axonal loss, explaining the absence of conduction blocks and temporal dispersion. Early recognition is vital, as treatments differ radically: CIDP requires immunosuppression (steroids, IVIG), while POEMS mandates targeting the plasma cell clone (chemotherapy, autologous stem cell transplantation).

Limitations and Future Directions

This study’s small sample size (17 POEMS, 17 CIDP) limits statistical power. Larger cohorts are needed to validate TLI thresholds and refine diagnostic algorithms. Additionally, VEGF levels—a POEMS biomarker—were not assessed in CIDP patients, precluding direct comparison. Future research should integrate VEGF testing and advanced imaging (PET-CT, skeletal surveys) to enhance diagnostic precision.

Conclusion

POEMS syndrome can be distinguished from CIDP through clinical vigilance and electrophysiological profiling. Neuropathic pain, systemic features (edema, organomegaly), thrombocytosis, and high TLI are red flags prompting further investigation. Combining serum M-protein testing with TLI analysis improves early detection, ensuring timely intervention. Clinicians must maintain a high index of suspicion for POEMS in patients with atypical demyelinating neuropathy, particularly when systemic manifestations coexist.

DOI: https://doi.org/10.1097/CM9.0000000000000318

Was this helpful?

0 / 0